Home › Blood Cancers › NCT05768269

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

A Long-Term Follow-up Study for Subjects Previously Treated With A Century Therapeutics Cellular Therapy Product

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Participant has provided written informed consent prior to any long-term follow-up (LTFU) study-specific procedures.
* Participants received at least one treatment with a cellular therapy product in an eligible index trial.
* Participant was withdrawn, early discontinued or completed an eligible index trial.
* Participant is willing and able to comply with scheduled visits, study plan, and other study procedures.

Exclusion Criteria:

-This study has no exclusion criteria.

About the study

This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.

What is being tested

• No Intervention (other)

Sponsor: Century Therapeutics, Inc. · Participants: 375 · Started: Apr 29, 2024

Contact the study team

• Century Therapeutics Clinical Team · Phone: 8885067670

Official record on ClinicalTrials.gov — NCT05768269

Locations in the U.S.

Conditions

• Blood Cancers
• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.